16-Mar-2026
No headlines found.
No press releases found.
No news found.
The Invesco Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Index is comprised of securities of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.
Invesco Biotechnology & Genome ETF trades on the ARCA stock market under the symbol PBE.
As of March 16, 2026, PBE stock price climbed to $77.24 with 41,324 million shares trading.
PBE has a market cap of $244.08 million. This is considered a Small Cap stock.
In the last 3 years, PBE traded as high as $85.73 and as low as $52.47.
PBE has underperformed the market in the last year with a price return of +20.7% while the SPY ETF gained +22.6%. PBE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.6% and -5.8%, respectively, while the SPY returned -1.6% and -2.5%, respectively.
PBE support price is $75.19 and resistance is $77.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PBE shares will trade within this expected range on the day.
